Ephedra Product & Ephedrine HCL Warnings

Description:
Ephedrine HCL 25mg 100 tablets from Kaizen.

EPHEDRINE HCL (Hydro Choride) is synthetic and pharmaceutical grade. It is an over the counter drug.

What does it do?

Use as Bronchial Dialator (for asthma)
Side effects are: Increased energy, decrease fat, preserves muscle tissue from breaking down.
-------------------------------------------------------------------------------
Ephedrine HCL Customer Reviews
Click here for review's from some of our customers who've tried Ephedrine HCL.
--------------------------------------------------------------------------------
What's in it?
Serving size: 1 tablet
Servings per bottle: 100
Amount per serving:
25 mg Epherdrine HCL
200 mg Guaifenesin

Suggested use:
Adults and children 12 years of age and over - oral dosage is 1 tablet every 4 hours, not to exceed 6 tablets in 24 hours or as directed by a physician. Do not exceed recommended dose unless directed by a physician.

Warnings:
Children under 12 years of age - consult physician. As with any medication, if you are pregnant or nursing a baby, seek the advice of a health professional before using this product.

Do not use this product unless a diagnosis of asthama has been made by a doctor. Do not use this product if you have heart disease, diabetes, or difficulty in urination due to enlargement of the prostate gland, if you have ever been hospitalized for asthma, or if you are taking any prescription drug for asthma unless directed by a physician. Some users of this product may experience nervouzness, tremors, sleeplessness, nausea and loss of appetite. Do not continue to use this product, but seek medical assistance if symptoms are not relieved within one hour or become worse. Do not use this product if you are presently taking a prescription drug for high blood pressure or depression without consulting a physician.

DRUG INTERACTION PRECAUTION: Do not use this product if you are a presently taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for two weeks after stopping the MAOI drug. If your are uncertain whether your prescription drug contains an MAOI, consult a health professional before taking this product.

FDA warning on Ephedrine

Note: Ephedrine HCL is currently on manufactuer back order. A new shipment is expected in mid March. We apologize for the inconvenience.

Phillip Konkle - wuss_man@hotmail.com
Epgedra Diet Pills are great for reducing your appetite and burning fat, it is also super for giving your work-outs a turbo boost. Work-outs with this can not even compare to workouts with out it.

JeffandDanae@aol.com
I was looking for something to give me an extra boost of energy for my busy college life. I ordered Ephedrine Hcl Hopeing That this product would do it. I was rather disappointed in the results. I actualy felt more tired and also had a slight headache. Maybe it works for some people, but definetly not for me.....Jeff Means

Jennifer Dale - jenniferdale@luther.co.uk
I was rather disappointed with this product. i thought it would reduce my appetite and burn some fat. instead it gave me a headache and had little effect on my appetite!

Lise Collins - new.leaf@sympatico.ca
I myself had headaches with this product, but my headaches stopped once I avoided caffeine and took white willow bark, now they worked great, I found that my cravings are completely gone, I craved a lot of chocolate, but the Ephedrine eliminated all my cravings and also have the energy to work out, which I haven't done in years, I feel like I am loosing weight without even trying. Thanks a bunch...

--------------------------------------------------------------------------------
Have you tried Ephedrine HCL? Post a review...get a discount!

If you would like to give your review of this product (good or bad) to be posted here, please email us at reviews@musclesurf.net. As a thank you, anyone who submits a review will receive a discount coupon for their next purchase!

FDA warning on Ephedrine
This response submitted by EdNak on 12/20/99.
Email Address:

HHS NEWS
U.S. Department of Health and Human Services
Food and Drug Administration

Arthur Whitmore: (202) 205-4144
Broadcast Media: (301) 827-3434
Consumer Hotline: (301) 532-4440

P97-15
June 2, 1997
--------------------------------------------------------------------------------

The Food and Drug Administration today proposed to reduce risks associated with dietary supplement products containing ephedrine alkaloids by limiting the amount of ephedrine alkaloids in products and requiring labeling and marketing measures that give adequate warning and information to consumers.

Ephedrine alkaloids are amphetamine-like compounds with potentially powerful stimulant effects on the nervous system and heart. Hundreds of consumer illnesses and injuries associated with the use of these products have been reported.

The proposal would not ban dietary supplements that contain ephedrine alkaloids.

"Consumers should be aware that just because a product is labeled 'natural' or from an herbal source it is not guaranteed to be safe," said Dr. Michael Friedman, Deputy Commissioner of Food and Drugs. "The effects of ephedrine alkaloids are potentially powerful ones. We urge people to talk to their doctors before using dietary supplements containing ephedrine alkaloids, and to always use them with caution."

Because ephedrine alkaloids are heart and nervous system stimulants, certain individuals including those with hypertension, heart conditions and neurologic disorders, should avoid their use. Pregnant women, too, should avoid the use of dietary supplements with ephedrine alkaloids.

The proposal would prohibit the marketing of dietary supplements containing 8 milligrams or more of ephedrine alkaloids per serving. Labeling that recommends or suggests conditions of use that would result in an intake of 8 mg or more in a 6-hour period or a total daily intake of 24 mg or more also would not be allowed.

In addition, the proposal would require label statements instructing consumers not to use the product for more than 7 days, and would not allow label claims for uses for which long-term intake would be necessary to achieve the purported effect. These safety measures are based on the fact that long-term intake of ephedrine alkaloids increases the likelihood of serious adverse events.

Another measure in the proposal would apply to products with claims that encourage short-term excessive intake to enhance the claimed effect, such as energy enhancement. Such products would be required to bear a labeling statement that "Taking more than the recommended serving may result in heart attack, stroke, seizure or death."

The proposal also would prohibit the use of other stimulant ingredients such as botanical sources of caffeine with ephedrine alkaloids because the combination increases the stimulant effects of ephedrine alkaloids and the chance of consumer injury.

Dietary supplement products containing ephedrine alkaloids are currently sold for a variety of purposes including weight loss, increased energy and body building.

Since 1994 the agency has received and investigated more than 800 reports of adverse events associated with the use of these products. Reported adverse events range from episodes of high blood pressure, irregularities in heart rate, insomnia, nervousness, tremors and headaches, to seizures, heart attacks, strokes and death. Most events occurred in young to middle aged, otherwise healthy adults using the products for weight control and increased energy.

Ephedrine alkaloids in dietary supplements are usually derived from one of several species of herbs of the genus Ephedra, sometimes called Ma huang, Chinese Ephedra and epitonin. Other botanical sources include Sida cordifolia.

The proposed measures were developed based on FDA's review of its adverse event reports, the scientific literature, and public comments reviewed by the agency, including comments generated by an October 1995 advisory working group public meeting and an August 1996 public meeting of FDA's Food Advisory Committee. These experts suggested a number of steps the agency might take to reduce injuries associated with use of dietary supplements containing ephedrine alkaloids.

FDA invites written comments on the proposal from the public and industry, which may be submitted to the Dockets Management Branch, HFA-305, Food and Drug Administration, 12410 Parklawn Drive, Room 1-23, Rockville, MD 20857. The closing date for comments is August 18, 1997.

Comments received to date and in response to the proposal are available for public examination in public docket No. 95N-0304 located in the Dockets Management Branch Office. All comments received will be reviewed and considered by the agency in developing the final rule.

These forums are maintained by the Department of Neurology at Massachusetts General Hospital
John Lester - Webspinner